91ÑÇÉ«´«Ã½

Annual Meeting

Engelking seeks to balance research and medicine

Ken Farabaugh
Jan. 19, 2023

When he was young, Luke Engelking’s mother asked him what he wanted to be when he grew up. His answer? “’A mad scientist,’” he said.

Engelking certainly was exposed to the idea of a career in science and medicine early, as his mother pursued a second career as a physician’s assistant during his high school years. “Unfortunately, she had a number of rare autoimmune diseases and was often in and out of doctors’ offices,” Engelking said. “From then on, I always knew I wanted to go to med school. However, I wasn’t always certain that I wanted a Ph.D.”

Luke Engelking
Luke Engelking

Engelking ended up doing both. He went to medical school at the University of Texas Southwestern Medical Center, where he got his M.D.–Ph.D. in the lab of Nobel laureates Michael Brown and Joe Goldstein, best known for their discovery of the low-density lipoprotein receptor and its regulation of cholesterol metabolism. He enjoyed working with Brown and Goldstein.

“It was a very productive time,” Engelking said. “I really didn’t appreciate working under their aegis when I was doing it. … Once you’re out on your own, everything is more of a struggle.”

Engelking has embraced that struggle. After a residency at Massachusetts General Hospital and a clinical and research fellowship back at UT Southwestern, he not only began seeing patients as an attending physician but also opened his own research lab as an assistant professor in the departments of internal medicine and molecular genetics, studying the role of sterol receptor element-binding proteins in colon cancer growth and progression.

Now an associate professor, Engelking balances his time between seeing patients and conducting research. In addition, he is working to establish a clinical research program in colon cancer genetics so data on mutations of enrolled patients can be made publicly available to researchers at UT Southwestern and around the world.

“It’s my hope that we’ll be able to synergize the clinical work with the work going on in the lab,” he said. “It’s a challenge to try to get all of this work to align — I hope I’m making progress, but we’re not quite there yet.”

Identifying markers of cancer cell proliferation in the intestine

As a physician, Luke Engelking practices adult gastroenterology, focusing on patients with inherited mutations that lead to colorectal cancers as in Lynch and familial adenomatous polyposis, or FAP, syndromes.

In the Engelking lab, research focuses on the roles of lipids in intestinal epithelial cell growth. The lab uses Cre-lox and CRISPR tools to alter gene expression, RNA-seq and lipidomics to profile cell markers, and intestinal organoids from both humans and mice as model systems.

The researchers hope that discovering novel mechanisms by which sterol receptor element-binding proteins, or SREBPs, regulate tumor cell growth and proliferation will present new drug targets for the treatment of colon cancer. Recently, the lab demonstrated that selective loss of SREBP-2, which blocks cholesterol synthesis, leads to overgrowth and increased proliferation of intestinal progenitor cells.

“What I really hope to do is move toward patient-oriented studies,” Engelking said. “Perhaps we’ll find patients with FAP phenotypes but unknown genetic markers. There are any number of genetic unknowns that impact underlying cancer biology.”

Enjoy reading 91ÑÇÉ«´«Ã½ Today?

Become a member to receive the print edition four times a year and the digital edition monthly.

Learn more
Ken Farabaugh

Ken Farabaugh is a former 91ÑÇÉ«´«Ã½ science editor.

Related articles

From the journals: JLR
Caleigh Findley
From the Journals: JLR
Vanshika Patel
Meet Robert Helsley
Christopher Radka
From the journals: JLR
Carmen Morcelle
From the journals: JLR
Swarnali Roy

Get the latest from 91ÑÇÉ«´«Ã½ Today

Enter your email address, and we’ll send you a weekly email with recent articles, interviews and more.

Latest in People

People highlights or most popular articles

Hidden strengths of an autistic scientist
Essay

Hidden strengths of an autistic scientist

April 3, 2025

Navigating the world of scientific research as an autistic scientist comes with unique challenges —microaggressions, communication hurdles and the constant pressure to conform to social norms, postbaccalaureate student Taylor Stolberg writes.

Richard Silverman to speak at 91ÑÇÉ«´«Ã½ 2025
91ÑÇÉ«´«Ã½ Annual Meeting

Richard Silverman to speak at 91ÑÇÉ«´«Ã½ 2025

March 27, 2025

Richard Silverman and Melissa Moore are the featured speakers at the 91ÑÇÉ«´«Ã½ annual meeting to be held April 12-15 in Chicago.

Women’s History Month: Educating and inspiring generations
Observance

Women’s History Month: Educating and inspiring generations

March 27, 2025

Through early classroom experiences, undergraduate education and advanced research training, women leaders are shaping a more inclusive and supportive scientific community.

91ÑÇÉ«´«Ã½ honors Lawrence Tabak with public service award
Award

91ÑÇÉ«´«Ã½ honors Lawrence Tabak with public service award

March 26, 2025

He will deliver prerecorded remarks at the 2025 91ÑÇÉ«´«Ã½ Annual Meeting in Chicago.

91ÑÇÉ«´«Ã½ names 2025 JBC/Tabor Award winners
Award

91ÑÇÉ«´«Ã½ names 2025 JBC/Tabor Award winners

March 24, 2025

The six awardees are first authors of outstanding papers published in 2024 in the Journal of Biological Chemistry.

Daniel N. Hebert (1962–2024)
Retrospective

Daniel N. Hebert (1962–2024)

March 17, 2025

Daniel Hebert’s colleagues remember the passionate glycobiologistscientist, caring mentor and kind friend.